Saturday 17 October 2026 Export DNLI’s income statement to Excel — free account

Denali Therapeutics Inc.

In the quarter to June 2026, revenue fell 89.7%, EPS grew 5.56%, free cash flow fell 22.9% and total debt fell 1.76%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

17.56 0.78 −4.25%

Follow DNLI

Alert me

Market cap: $2.9B
P/E: 0.0×
Fwd P/E: −7.7×
Dividend yield: —
F-score: 4/9
Altman Z: 13.78
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.24

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	2	—	—	—	—	—	—	1	2	—

Insider Ownership 20.08%

Capital & Financial Ratios $m

Market Cap 2,930.00

Revenue 298.99

Net Income (511.45)

Free Cash Flow (437.46)

Net Debt (704.99)

Current Ratio 8.37

Debt/Equity 0.01

P/E ratio 0.00

Fwd P/E (7.70)

P/S ratio 11.00

P/B ratio 3.94

Past 5Y EPS Growth —

This Y EPS Growth 22.82%

Next Y EPS Growth (2.24%)

Next Y revenue growth (96.25%)

Next 5Y EPS Growth 16.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 29.69%

10-year low 10-year high

P/B against its own 10 years 58.37%

10-year low 10-year high

EV/Sales against its own 10 years 33.11%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,035	832	868	710
Receivables	—	—	—	4
Inventory	—	—	—	4
Other	—	—	—	—
	1,064	864	901	754

	2023	2024	2025	Q'26
Payables	9	11	3	12
ST’ Debt	—	—	—	—
Other	—	—	—	—
	78	102	98	90

Compound Annual Growth %

	10y	5y	3y
Sales	—	20.67%	(0.51%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	40.99%	(2.50%)	(0.93%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	4	—	—	—
’23	35	294	1	0	331
’22	42	52	4	10	108
’21	8	23	5	13	49
’20	4	6	9	317	336
’19	4	4	14	5	27

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(131)	(97)	—	—	—
’25	(131)	(75)	(107)	(99)	(413)
’24	(114)	(91)	(59)	(84)	(348)
’23	(59)	(113)	(87)	(99)	(358)
’22	(72)	(43)	(57)	(73)	(245)
’21	(50)	(54)	(41)	(65)	(211)
’20	(54)	(43)	0	514	416

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(134)	(98)	—	—	—
’25	(137)	(80)	(106)	(100)	(422)
’24	(116)	(96)	(63)	(89)	(364)
’23	(62)	(119)	(89)	(101)	(371)
’22	(76)	(46)	(63)	(78)	(263)
’21	(53)	(55)	(43)	(69)	(220)
’20	(55)	(44)	(1)	513	413

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.69)	(0.68)	—	—	—
’25	(0.78)	(0.72)	(0.74)	(0.73)	(2.97)
’24	(0.68)	(0.59)	(0.63)	(0.67)	(2.57)
’23	(0.80)	1.30	(0.72)	(0.86)	(1.06)
’22	(0.53)	(0.48)	(0.84)	(0.75)	(2.60)
’21	(0.58)	(0.50)	(0.69)	(0.62)	(2.39)
’20	(0.55)	(0.56)	(0.54)	1.91	0.63

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	14.72	12.32	14.24	12.39	41.10	20.24	15.45	14.56	10.57	Analyst estimates 2026–2028 Powerpack
	High	—	22.95	25.79	28.87	93.94	84.25	47.47	33.31	33.33	24.35
People
People	Employees	125	130	179	261	291	380	427	445	422	503
	Revenue/emp, $m	0.00	0.00	0.72	0.10	1.15	0.13	0.25	0.74	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	129	27	336	49	108	331	—	—
	Gross margin, %	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00	—	—
	EBT	(87)	(88)	(36)	(198)	72	(291)	(326)	(145)	(423)	(512)
	EBT margin, %	0.00	0.00	(28.06)	(742.05)	21.44	(598.34)	(300.54)	(43.93)	0.00	0.00
	Net income	(87)	(88)	(36)	(198)	71	(291)	(326)	(145)	(423)	(513)
	Depreciation	2	4	5	3	9	17	9	(27)	(27)	1
Per share, $
Per share, $	Revenue	0.00	0.00	1.39	0.28	3.08	0.40	0.86	2.41	0.00	0.00
	Earnings	(13.49)	(5.89)	(0.39)	(2.07)	0.65	(2.39)	(2.60)	(1.06)	(2.57)	(2.97)
	Cash flow	(11.19)	(5.12)	0.54	(1.59)	3.82	(1.74)	(1.95)	(2.61)	(2.11)	(2.39)
	Capex	(0.95)	(0.19)	(0.04)	(0.19)	(0.03)	(0.07)	(0.14)	(0.09)	(0.10)	(0.05)
	Free cash flow	(12.15)	(5.31)	0.50	(1.77)	3.79	(1.81)	(2.09)	(2.70)	(2.21)	(2.44)
	Book value	39.61	31.13	5.90	4.13	10.56	7.92	8.30	7.50	7.48	5.87
	Shares, m	6	15	93	96	109	122	126	137	164	173
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	214.77	0.00	0.00	0.00	—	—
	P/S	—	—	14.82	62.43	27.19	111.38	31.98	8.89	—	—
	P/B	—	—	3.50	4.22	7.93	5.63	3.33	2.85	—	—
	EV/Sales	—	—	11.22	49.45	23.01	94.81	20.15	5.90	—	—
	EV/FCF	—	—	31.02	(7.78)	18.69	(20.98)	(8.32)	(5.26)	—	—
Cash, $m
Cash, $m	Operating cash flow	(72)	(77)	50	(152)	416	(211)	(245)	(358)	(348)	(413)
	Capex	(6)	(3)	(3)	(18)	(3)	(8)	(18)	(13)	(16)	(10)
	Free cash flow	(78)	(80)	47	(169)	413	(220)	(263)	(371)	(364)	(422)
Balance, $m
Balance, $m	Working capital	173	395	448	385	1,424	519	1,008	986	762	802
	Total debt	—	—	—	69	64	59	53	—	6	6
	Net debt	(178)	(406)	(464)	(346)	(1,406)	(806)	(1,283)	(1,035)	(827)	(862)
	Shareholders’ equity	255	466	547	395	1,151	962	1,042	1,031	1,230	1,014
Returns, %
Returns, %	ROA	(56.31)	(23.27)	(6.31)	(32.52)	6.59	(19.32)	(22.76)	(11.11)	(33.45)	(40.69)
	ROIC	(71.72)	(94.57)	(35.11)	(274.53)	0.00	(118.58)	0.00	0.00	(75.59)	(229.23)
	ROE	157.85	(47.46)	(7.16)	(41.97)	9.21	(27.51)	(32.52)	(14.01)	(37.40)	(45.69)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
XENE Xenon Pharmaceuticals Inc.	$3.3B	— (loss-making)	— (loss-making)	+100.70% (above 0%: growing)	n/m	−48.57% (below 0%: shrinking)	100.00%	0.00%	Compare
IDYA IDEAYA Biosciences, Inc.	$3.3B	— (loss-making)	— (loss-making)	+125.77% (above 0%: growing)	n/m	−41.09% (below 0%: shrinking)	100.00%	(1,380.73%)	Compare
CELC Celcuity, Inc.	$3.0B	— (loss-making)	—	—	n/m	−53.27% (below 0%: shrinking)	0.00%	0.00%	Compare
DNLI Denali Therapeutics Inc.	$2.9B	— (loss-making)	— (loss-making)	−89.74% (below 0%: shrinking)	n/m	−22.91% (below 0%: shrinking)	97.42%	(3,622.11%)
RCUS Arcus Biosciences, Inc.	$2.9B	— (loss-making)	— (loss-making)	−74.38% (below 0%: shrinking)	n/m	+10.53% (above 0%: growing)	100.00%	(234.15%)	Compare
ELVN Enliven Therapeutics, Inc.	$2.9B	— (loss-making)	—	—	n/m	−8.34% (below 0%: shrinking)	0.00%	0.00%	Compare
DYN Dyne Therapeutics, Inc.	$2.9B	— (loss-making)	—	—	n/m	−39.08% (below 0%: shrinking)	0.00%	0.00%	Compare
NRIX Nurix Therapeutics, Inc.	$2.7B	9.7×	— (loss-making)	+8,426.27% (above 0%: growing)	n/m	+1,122.10% (above 0%: growing)	100.00%	83.12%	Compare
ZLAB Zai Lab Limited Unsponsored ADR	$2.7B	— (loss-making)	— (loss-making)	−3.33% (below 0%: shrinking)	n/m	−84.42% (below 0%: shrinking)	54.70%	(71.95%)	Compare
Median of peers	$2.9B	—	—	+100.70%	—	−40.08%	77.35%	0.00%

All 614 Biotechnology stocks →

Denali Therapeutics Inc. (DNLI) key facts

Concern: Denali Therapeutics Inc. reported a net loss of $512.5 million, or a loss of $2.97 per share, for fiscal 2025.
Denali Therapeutics Inc. (DNLI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, DNLI traded at $17.56, a market capitalization of $2.9 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 11.0× sales.
Return on equity was −45.7% and debt-to-equity 0.01.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 13.78 (safe zone) for fiscal 2023.